Generic filters

Molgenium is a trusted leader in the field of ATMP development and production, supported by a team of expert scientists and CMC professionals with a proven track record of success. We provide comprehensive end-to-end support, guiding you through the entire development process from initial stages to regulatory approval, clinical exemption, and market launch. Our commitment to excellence is exemplified through our rigorous product analytical processes and patient-centric approach, ensuring that the ATMP product meets regulatory compliance standards while delivering safe and effective outcomes. Our innovative AI-driven risk-based approach and cutting-edge technology are tailored to optimize product safety and efficacy, paving the way for the successful commercialization of your ATMP. Choose Molgenium and achieve your ATMP development goals with confidence.

Molgenium has set forth several key objectives to achieve its mission

First, it seeks to enhance engagement and collaboration with various support organizations, including the EMA, industry, and other stakeholders. This will ensure that they receive the necessary support and resources to succeed.

Second, Molgenium aims to comprehensively cover the entire product development process, providing support at every stage of the journey. This will help to improve the success rate of product development and ensure that support is available throughout the process.

Third, Molgenium is committed to focusing on innovative products that address unmet medical needs and have a high potential for success, as well as products that offer significant health benefits to patients.

Finally, Molgenium recognizes the importance of transparency in both ATMP trials and the use of the application on patients. By promoting transparency and sharing information on successes and failures, Molgenium aims to facilitate learning among organizations in this field.

Daily update of new cell therapies worldwide








Data sources